Jazz Pharmaceuticals Public Limited Company filed a current report on September 23, 2026, disclosing that its subsidiary Jazz Financing Lux S.à r.l. entered into Amendment No. 4 to its Credit Agreement, repricing and extending the maturity of its existing U.S. dollar term loan facility.

Key Highlights

  • New tranche established: Tranche B-3 Dollar Term Loans were created, with an outstanding principal amount of $1,895,000,000 immediately following the amendment.
  • Maturity extended: The maturity date was amended from May 5, 2028 to May 5, 2033.
  • Interest rate reduced: The applicable margin decreased by 50 basis points, to 1.75% for Term SOFR borrowings and 0.75% for prime lending rate borrowings.
  • Additional borrowing: Jazz Lux borrowed $273,310,355.18 in additional Tranche B-3 Dollar Term Loans to repay unconverted Tranche B-2 Dollar Term Loans.
  • Amortization schedule: The Tranche B-3 Dollar Term Loans amortize in quarterly installments equal to 0.25% of the initial principal amount, with the remaining balance due May 5, 2033.
  • SOFR floor: The Tranche B-3 Dollar Term Loans are subject to a Term SOFR floor of 0.50% and will not be subject to a credit spread adjustment.

Jazz Pharmaceuticals Amends Credit Agreement with Tranche B-3 Dollar Term Loans

According to the filing, Jazz Financing Lux S.à r.l., a wholly owned Luxembourg subsidiary of Jazz Pharmaceuticals Public Limited Company (NASDAQ:JAZZ), entered into Amendment No. 4 (the "Repricing Amendment") to the Credit Agreement originally dated May 5, 2021. The amendment was executed on September 23, 2026, with the stated purpose of extending the maturity date and repricing the outstanding Tranche B-2 Dollar Term Loans. Bank of America, N.A. serves as administrative agent and U.S. Bank Trust Company, National Association serves as collateral trustee under the Amended Credit Agreement.

The filing states that upon entry into the Amended Credit Agreement, certain existing lenders converted their outstanding Tranche B-2 Dollar Term Loans into the new Tranche B-3 Dollar Term Loans, while Jazz Lux borrowed an additional $273,310,355.18 in aggregate principal to repay the Tranche B-2 Dollar Term Loans that were not converted. The filing notes that the principal amount of Tranche B-2 Dollar Term Loans outstanding immediately prior to the amendment and the outstanding principal amount of Tranche B-3 Dollar Term Loans immediately following the amendment each totaled $1,895,000,000.

The Tranche B-3 Dollar Term Loans bear interest at either Term SOFR or the prime lending rate plus an applicable margin, according to the filing. The applicable margin of 1.75% for Term SOFR borrowings and 0.75% for prime rate borrowings represents a decrease of 50 basis points from the margins on the prior Tranche B-2 Dollar Term Loans. The filing further notes that the new loans carry substantially the same material terms as predecessor tranches with respect to prepayment, security, covenants, and events of default. The amendment was signed by Philip L. Johnson, Executive Vice President and Chief Financial Officer.

What Was Disclosed

Jazz Pharmaceuticals disclosed the execution of Amendment No. 4 to its Credit Agreement, converting $1,895,000,000 in outstanding term loans into a new Tranche B-3 facility with a reduced interest rate margin and a maturity date extended by five years to May 5, 2033.